European gains are failing to lift Tel Aviv stocks, which are down 1.6% at Tuesday mid-day, after morning losses of 0.6%. Leading indices opened with 0.7% gains, which were quickly lost. The opening gains were associated with Monday's gains on Wall Street, where the Dow Jones climbed 1.44% and Nasdaq gained 1.53%. But ongoing regional violence is providing a negative counterforce.
The Maof-25 blue chip index is down 1.6% to 426.1 points and the TA-100 index is off 1.0% to 410.6 points. Technology shares are up 0.2%. Total turnover is low at NIS 175 million.
Teva Pharmaceuticals (Nasdaq:TEVA) is rising 1.5% on the session's biggest turnover NIS 17 million. Teva opened with 1.8% positive arbitrage spread after on Monday gaining 1.6%. On Monday Teva announced the U.S. Food and Drug Administration has granted it tentative approval for Quinapril HCL 5, 10, 20 and 40 milligram tablets. This is the first FDA tentative approval for Quinapril. The drug is the generic version of Parke Davis' Accupril for treating hypertension. Annual sales of the original drug come to $500 million.
Koor Industries (NYSE:KOR) is off 5.1% and Clal Industries is down 2.8%. The drops are attributed to affiliate ECI Telecom (Nasdaq:ECIL) plunging 16% on Monday. ECI reported $232.8 million revenue for Q4, 11% less than in Q3. Revenue was 7% less than the average estimate. Net loss came to $43.1 million. Yesterday, Koor dropped 3.8% and Clal Industries closed down 2%
Bank Discount is down 0.2% on big turnover of NIS 6.1 million after opening with 1.8% gains. The lively action is attributed to TheMarker's report on Monday that the bank is planning a Nasdaq IPO of its wholly-owned subsidiary Israel Discount Bank of New York. Leader DS estimated that the New York branch is worth at least $400 million.
Retalix (Nasdaq:RTLX) is up 0.6% after posting record revenue of $15.5 million in Q4, and $635,000 operating profit, compared with $151,000 in the parallel quarter of 2000. Net profit came to $635,000, compared with a loss of $427,000 in the parallel.